Evidence map›Paper›PMID 39919126›Full record

ArticlePLOS global public health2025

Treatment completion of drug-resistant tuberculosis in Ethiopia: A perspective from healthcare users.

Ahmed Reshid Tusho, Sheila Theresa Mokoboto-Zwane

Abstract read
In one paragraph

Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ahmed Reshid TushoDepartment of Tuberculosis and Leprosy, Oromia Health Bureau, Addis Ababa, Ethiopia.ORCID https://orcid.org/0000-0002-1372-2753
Sheila Theresa Mokoboto-ZwaneDepartment of Health Studies, College of Human Sciences, University of South Africa, Pretoria, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-resistant tuberculosis remains a persistent public health threat. Maximizing successful treatment completion is a global health priority and a focus of the End TB strategy. Despite the implementation of programmatic management for drug-resistant tuberculosis in Ethiopia, there is limited understanding of the barriers related to successful treatment completion among Ethiopian patients. A qualitative study that is explorative, descriptive and contextual in nature was conducted to explore and describe the views and lived experiences of previously treated drug-resistant tuberculosis patients to gain an in-depth understanding of barriers to the successful completion of drug-resistant tuberculosis treatment. Six focus group discussion sessions with 42 purposively selected drug-resistant tuberculosis patients with previous treatment history and on retreatment regimens were conducted. The seven prominent themes revealed were: drug-related challenges encompassing adverse events and the lengthy treatment duration; clinical hurdles such as delayed consultation following prolonged illness, diagnostic delays, and suboptimal dosages; psycho-emotional difficulties including emotional trauma and facing stigma from both the community and healthcare professionals; socio-economic constraints; service-related issues such as interruptions in monitoring tests, inadequate follow-up, and accessibility barriers; patient-related factors such as a false sense of recovery and reverting to previously quit habits; and provider-related issues such as lack of responsiveness and ineffective communication. Addressing these factors demands policy-level decisions and programmatic guidance at the national level based on best practices, as well as good programmatic implementation from actors through regional and health facility-level structures.

Identifiers

PMID39919126
PMCPMC11805356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.